Dublin, Aug. 12, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "NHL: Diffuse Large Bcell Lymphoma: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering. An increase in disease prevalence and the launch of new targeted therapies across a range of treatment settings will drive the growth of the diffuse large B-cell lymphoma (DLBCL) market during 2016-25 despite Rituxan's patent expiry. This report addresses the following questions: - What will drive the growth of the DLBCL market during 2016-25? - Which geographical market will be the most lucrative and which will experience the fastest growth? - Which branded therapies will have the largest impact on the DLBCL market? - Which therapies will target patient populations that represent unmet needs in DLBCL? - When will generic and biosimilar therapies enter the market and what impact will they have on revenues? Key Topics Covered: FORECAST: DIFFUSE LARGE B-CELL LYMPHOMA - Market Overview and Trends - Market Definition and Methodology - Afinitor (everolimus) - Biosimilar rituximab - Gazyva (obinutuzumab) - Imbruvica (ibrutinib) - Revlimid (lenalidomide) - Rituxan (rituximab) - Velcade (bortezomib) - Primary Research Methodology TREATMENT: DIFFUSE LARGE B-CELL LYMPHOMA - Primary Research Methodology - Disease Definition and Diagnosis - Patient Segmentation - Country Treatment Trees - Current Treatment Options - Prescribing Trends EPIDEMIOLOGY: DIFFUSE LARGE B-CELL LYMPHOMA - Disease Background - Sources and Methodology - Forecast: NHL Overall - Forecast: NHL Subtypes (incl. DLBCL, FL, and MCL) - Epidemiologist Insight - Strengths and Limitations MARKETED DRUGS: DIFFUSE LARGE B-CELL LYMPHOMA
- Product Overview - Product profile: Rituxan PIPELINE: DIFFUSE LARGE B-CELL LYMPHOMA - Clinical Pipeline Overview - Target Product Profile - Recently Discontinued Drugs - Product profile (late stage): Afinitor - Product profile (late stage): Gazyva - Product profile (late stage): Imbruvica - Product profile (late stage): Keytruda - Product profile (late stage): Revlimid - Product profile (late stage): Velcade For more information about this report visit http://www.researchandmarkets.com/research/ck...hl_diffuse Related Topics: Lymphoma Drugs
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716